Pradaxa Lawsuits on the Rise: Next Trial to Begin Sept. 2018
Pradaxa Lawsuits on the Rise: Next Trial to Begin Sept. 2018
Introduction
Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals Inc. is an anticoagulant prescribed to prevent blood clots and reduce the risk of stroke. The drug which was approved by FDA in 2010, allegedly caused serious injuries like internal bleeding in several patients. Some reports indicate Pradaxa use led to gastrointestinal bleeding, heart attack, stroke, brain hemorrhage, kidney bleeding, and death.
In 2014, the drug maker agreed to settle more than 4,100 lawsuits for $650 million. More than 2,400 lawsuits, filed after that settlement, are pending in the state court against Boehringer Ingelheim. The first two trials held in March 2018 and May 2018 concluded verdicts in favor of the defendants. The next set of trials are slated to begin in September 2018 and February 2019.
In December 2017, Judge Herndon recommended termination of Pradaxa multidistrict litigation (MDL 2385; In Re: Pradaxa [Dabigatran Etexilate] Products Liability Litigation), which was formed in 2012 in the Southern District of Illinois.
Comments
Latest News
Oregon to Get $66M in Sackler Opioid Settlement
Categories: Opioids
Oregon will gain $66 million as part of a nationwide settlement with the Sackler family and Purdue Pharma, the makers of OxyContin. The funds will be used to expand and…
Study Finds Toxic Metals in E-Cigs and U-Cigs Vapors
Categories: E-Cigarette: JUUL
As health concerns about e-cigarette use escalate, emerging research suggests that a newer class of vaping products—ultrasonic cigarettes or u-cigarettes—may pose even greater risks.
A study published in Environmental Health Perspectives in…
Appeals Court Upholds $611M Roundup Verdict
Categories: Roundup
A Missouri appeals court has upheld a massive Roundup verdict originally totaling $1.5 billion, but significantly reduced the final amount Bayer and its Monsanto unit must pay to $611 million.
The case involved three plaintiffs from New…